AstraZeneca today announced the FDA has granted Orphan Drug Status for Fasenra (benralizumab) for Eosinophilic Granulomatosis with Polyangiitis (EGPA). Fasenra is also approved for severe, eosinophilic asthma https://t.co/4ChX8D5Evx